Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | NAMPT | P43490 | 4/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | DRD3 | P35462 | 1/20 | 0.48 |
| ▸ | JAK1 | P23458 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25875892 | 0.95 | CYP1A2 (0.64) | CYP1A2CYP2D6CYP2C19ALDH1A1EPHX2 | |
| SCHEMBL21845767 | 0.89 | JAK2 (0.57) | NAMPTSMN1; SMN2TSHRJAK1 | |
| SCHEMBL21845749 | 0.84 | JAK2 (0.59) | CYP1A2CYP2D6CYP2C19NAMPTEPHX2 | |
| SCHEMBL25875908 | 0.83 | NPC1 (0.69) | ALDH1A1SMN1; SMN2POLB | |
| SCHEMBL4872075 | 0.77 | SIGMAR1 (0.68) | CYP2D6CYP2C19KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL25875912 | 0.76 | RAB9A (0.54) | — | |
| SCHEMBL25875900 | 0.75 | EPHX1 (0.60) | NAMPT | |
| SCHEMBL22752150 | 0.75 | JAK2 (0.61) | NAMPTJAK1 | |
| SCHEMBL25875896 | 0.75 | DRD4 (0.66) | CYP1A2CYP2D6CYP2C19NAMPTTSHR | |
| SCHEMBL25875888 | 0.74 | MAOA (0.53) | CYP1A2KDM4ESMN1; SMN2EPHX2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230227430-A1 | ARYL CYCLOPROPYL-AMINO-ISOQUINOLINYL AMIDE COMPOUNDS | ALCON INC. (CH) | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227430-A1 | ARYL CYCLOPROPYL-AMINO-ISOQUINOLINYL AMIDE COMPOUNDS | UACA, CHUK, MAP3K2 | CYP1A2 4237/4885CYP2D6 4757/4885CYP2C19 4754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.